Prelude announces acceptance of multiple preclinical abstracts at the 2024 aacr annual meeting

Wilmington, del., march 05, 2024 (globe newswire) -- prelude therapeutics incorporated (nasdaq: prld), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the company's highly selective oral smarca2 degrader, its potentially best-in-class cdk9 inhibitor and its next-generation cdk4/6 inhibitor, have been accepted for presentation at the american association for cancer research (aacr) annual meeting 2024, taking place from april 5 to 10, 2024.
PRLD Ratings Summary
PRLD Quant Ranking